Clinical Trial Update: Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating everolimus, bortezomib, and/or rituximab in relapsed/refractory Waldenström's macroglobulinemia; study terminated with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• Everolimus (everolimus)
• Rituximab (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-04-23